These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34004217)

  • 1. Characterization of Opalescence in low Volume Monoclonal Antibody Solutions Enabled by Microscale Nephelometry.
    Kingsbury JS; Lantz MM; Saini A; Wang MZ; Gokarn YR
    J Pharm Sci; 2021 Sep; 110(9):3176-3182. PubMed ID: 34004217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opalescence Measurements: Improvements in Fundamental Knowledge, Identifying Sources of Analytical Biases, and Advanced Applications for the Development of Therapeutic Proteins.
    Barros M; Zhang X; Kenrick S; Valente JJ
    J Pharm Sci; 2021 Nov; 110(11):3550-3557. PubMed ID: 34111445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimerization Dictates Solution Opalescence of a Monoclonal Antibody.
    Yang TC; Langford AJ; Kumar S; Ruesch JC; Wang W
    J Pharm Sci; 2016 Aug; 105(8):2328-37. PubMed ID: 27373839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opalescence in monoclonal antibody solutions and its correlation with intermolecular interactions in dilute and concentrated solutions.
    Raut AS; Kalonia DS
    J Pharm Sci; 2015 Apr; 104(4):1263-74. PubMed ID: 25556561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding opalescence measurements of biologics - A comparison study of methods, standards, and molecules.
    Kunz P; Stuckenberger E; Hausmann K; Gentiluomo L; Neustrup M; Michalakis S; Rieser R; Romeijn S; Wichmann C; Windisch R; Hawe A; Jiskoot W; Menzen T
    Int J Pharm; 2022 Nov; 628():122321. PubMed ID: 36273703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation.
    Salinas BA; Sathish HA; Bishop SM; Harn N; Carpenter JF; Randolph TW
    J Pharm Sci; 2010 Jan; 99(1):82-93. PubMed ID: 19475558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine suppresses opalescence and liquid-liquid phase separation in IgG solutions.
    Oki S; Nishinami S; Shiraki K
    Int J Biol Macromol; 2018 Oct; 118(Pt B):1708-1712. PubMed ID: 29981328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical Perspective on Opalescence and Liquid-Liquid Phase Separation in Protein Solutions.
    Raut AS; Kalonia DS
    Mol Pharm; 2016 May; 13(5):1431-44. PubMed ID: 27017836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine and its Derivatives Suppress the Opalescence of an Antibody Solution.
    Oki S; Nishinami S; Nakauchi Y; Ogura T; Shiraki K
    J Pharm Sci; 2022 Apr; 111(4):1126-1132. PubMed ID: 34843741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opalescence Arising from Network Assembly in Antibody Solution.
    Nakauchi Y; Nishinami S; Murakami Y; Ogura T; Kano H; Shiraki K
    Mol Pharm; 2022 Apr; 19(4):1160-1167. PubMed ID: 35274955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
    Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
    MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation.
    Mason BD; Zhang L; Remmele RL; Zhang J
    J Pharm Sci; 2011 Nov; 100(11):4587-96. PubMed ID: 21638285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smartphone-based turbidity reader.
    Ceylan Koydemir H; Rajpal S; Gumustekin E; Karinca D; Liang K; Göröcs Z; Tseng D; Ozcan A
    Sci Rep; 2019 Dec; 9(1):19901. PubMed ID: 31882742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
    Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AF4 and PEG Precipitation as Predictive Assays for Antibody Self-Association.
    Condado-Morales I; Sokolova V; Wahlund PO; Heding KE; Auclair S; Kingsbury JS; Arosio P; Lorenzen N
    Mol Pharm; 2023 Feb; 20(2):1323-1330. PubMed ID: 36668814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties.
    Starr CG; Makowski EK; Wu L; Berg B; Kingsbury JS; Gokarn YR; Tessier PM
    Mol Pharm; 2021 Jul; 18(7):2744-2753. PubMed ID: 34105965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association.
    Sukumar M; Doyle BL; Combs JL; Pekar AH
    Pharm Res; 2004 Jul; 21(7):1087-93. PubMed ID: 15290846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-Protein Interactions of Highly Concentrated Monoclonal Antibody Solutions via Static Light Scattering and Influence on the Viscosity.
    Hung JJ; Dear BJ; Karouta CA; Chowdhury AA; Godfrin PD; Bollinger JA; Nieto MP; Wilks LR; Shay TY; Ramachandran K; Sharma A; Cheung JK; Truskett TM; Johnston KP
    J Phys Chem B; 2019 Jan; 123(4):739-755. PubMed ID: 30614707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements.
    Neergaard MS; Kalonia DS; Parshad H; Nielsen AD; Møller EH; van de Weert M
    Eur J Pharm Sci; 2013 Jun; 49(3):400-10. PubMed ID: 23624326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biophysical Determinants for the Viscosity of Concentrated Monoclonal Antibody Solutions.
    Mosca I; Pounot K; Beck C; Colin L; Matsarskaia O; Grapentin C; Seydel T; Schreiber F
    Mol Pharm; 2023 Sep; 20(9):4698-4713. PubMed ID: 37549226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.